{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Berberine", "Gut microbiota", "Rheumatoid arthritis", "Targets", "Therapeutics"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33989762", "DateCompleted": {"Year": "2022", "Month": "02", "Day": "04"}, "DateRevised": {"Year": "2022", "Month": "02", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "05", "Day": "11"}], "Language": ["eng"], "ELocationID": ["10.1016/j.phrs.2021.105667", "S1043-6618(21)00251-6"], "Journal": {"ISSN": "1096-1186", "JournalIssue": {"Volume": "169", "PubDate": {"Year": "2021", "Month": "Jul"}}, "Title": "Pharmacological research", "ISOAbbreviation": "Pharmacol Res"}, "ArticleTitle": "Efficacy of berberine in treatment of rheumatoid arthritis: From multiple targets to therapeutic potential.", "Pagination": {"StartPage": "105667", "MedlinePgn": "105667"}, "Abstract": {"AbstractText": ["Rheumatoid arthritis is a systemic autoimmune disorder involved in persistent synovial inflammation. Berberine is a nature-derived alkaloid compound with multiple pharmacological activities in different pathologies, including RA. Recent experimental studies have clarified several determinant cellular and molecular targets of BBR in RA, and provided novel evidence supporting the promising therapeutic potential of BBR to combat RA. In this review, we recapitulate the therapeutic potential of BBR and its mechanism of action in ameliorating RA, and discuss the modulation of gut microbiota by BBR during RA. Collectively, BBR might be a promising lead drug with multi-functional activities for the therapeutic strategy of RA."], "CopyrightInformation": "Copyright \u00a9 2021. Published by Elsevier Ltd."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, China; National Engineering Laboratory for the Development of Southwestern Endangered Medicinal Materials, Guangxi Botanical Garden of Medicinal Plants, Nanning, Guangxi, China."}], "LastName": "Huang", "ForeName": "Dan-Na", "Initials": "DN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Engineering Laboratory for the Development of Southwestern Endangered Medicinal Materials, Guangxi Botanical Garden of Medicinal Plants, Nanning, Guangxi, China."}], "LastName": "Wu", "ForeName": "Fang-Fang", "Initials": "FF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, China."}], "LastName": "Zhang", "ForeName": "Ai-Hua", "Initials": "AH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, China."}], "LastName": "Sun", "ForeName": "Hui", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin, China; National Engineering Laboratory for the Development of Southwestern Endangered Medicinal Materials, Guangxi Botanical Garden of Medicinal Plants, Nanning, Guangxi, China. Electronic address: xijunw@sina.com."}], "LastName": "Wang", "ForeName": "Xi-Jun", "Initials": "XJ"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Pharmacol Res", "NlmUniqueID": "8907422", "ISSNLinking": "1043-6618"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0I8Y3P32UF", "NameOfSubstance": "Berberine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Arthritis, Rheumatoid"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Berberine"}, {"QualifierName": [], "DescriptorName": "Humans"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2021", "Month": "2", "Day": "2"}, {"Year": "2021", "Month": "5", "Day": "3"}, {"Year": "2021", "Month": "5", "Day": "6"}, {"Year": "2021", "Month": "5", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "5", "Day": "14", "Hour": "20", "Minute": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33989762", "10.1016/j.phrs.2021.105667", "S1043-6618(21)00251-6"]}}], "PubmedBookArticle": []}